The use of anti-TNF-α (adalimumab) treatment reduced the diseased joint structural progression compared to methotrexate, which was further reduced by use of the both drugs in combination in a study on 799 patients with active early RA (< 3 years since diagnosis) [115]. This evidence concerns the gene TNF and rheumatoid arthritis.